Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Does Cannabis Regulate Neuroimmune Responses in Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

The immune system plays an essential role in brain health. In dementia, neuroinflammation, an overactive immune response within the brain, contributes to neuron damage and disease progression. Because cannabinoids interact with immune-regulating pathways, researchers are investigating whether cannabis could help balance this response. 

However, according to NHS and NICE guidance, there is no proven clinical evidence that cannabis-based medical products regulate immune function or improve outcomes in people with dementia (NHS Guidance; NICE NG144; NICE NG97). 

Can medical cannabis be accessed legally for women’s health?

How The Neuroimmune System Works 

The brain’s immune defence involves specialised cells called microglia, which clear waste and respond to injury. In dementia, these cells become overactive, releasing inflammatory chemicals that damage healthy neurons. 

Cannabinoids such as THC and CBD act on CB1 and CB2 receptors of the endocannabinoid system (ECS), which are found on microglia and other immune cells. Laboratory studies suggest this interaction may reduce inflammatory signalling and oxidative stress, potentially protecting neurons from further harm. 

A 2024 review in Nature Reviews Neurology described cannabinoids as potential immune modulators, capable of dampening excessive neuroinflammation, but emphasised that this evidence is limited to animal and cell models, not human dementia trials (Nature Reviews Neurology, 2024). 

What Human Studies Show 

Human evidence remains limited and inconclusive. A 2023 randomised crossover trial in older adults with dementia found that THC/CBD formulations were well tolerated but showed no measurable changes in inflammatory or immune markers compared with placebo (PubMed Study, 2023). 

A 2024 feasibility study in Switzerland also observed mild behavioural improvements but no objective immune regulation, concluding that cannabinoids’ anti-inflammatory effects remain theoretical in clinical settings (Swiss Study, 2024). 

The Johns Hopkins Center for Psychedelic and Consciousness Research reaffirmed in 2024 that evidence for cannabinoids as neuroimmune regulators is preliminary and should be confined to research environments (Frontiers in Aging Neuroscience, 2024). 

The Clinical Bottom Line 

  • Cannabinoids influence immune signalling in laboratory studies but not proven in humans. 
  • No clinical trials show cannabis reduces brain inflammation or regulates immune function in dementia. 
  • NICE, NHS, WHO, and Johns Hopkins experts all consider this research experimental only. 
  • Any use should be limited to formal, specialist-supervised research trials. 

Educational Context: AlleviMed 

Educational organisations such as AlleviMed explain how cannabis eligibility is assessed in the UK. They highlight that immune regulation or neuroprotection are not licensed indications, and cannabis-based medicines are reserved for specific, evidence-backed conditions. 

Takeaway 

Cannabis may influence immune cells in the brain according to laboratory research, but no human studies confirm neuroimmune benefits in dementia. NHS, NICE, and WHO agree that these findings remain theoretical and unproven, reinforcing that cannabis should not be used outside clinical research trials. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories